Sheila Gujrathi - 28 Jul 2026 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Director
Issuer ticker: PCSA
Reported as of: 28 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jul 2026, 21:49:56 UTC
Prior SEC filing: 04 Mar 2026
Next SEC filing: 06 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Sheila Gujrathi

Key filing fact

Sheila Gujrathi filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 30 Jul 2026.

Key facts

This page summarizes Sheila Gujrathi's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Jul 2026, 21:49.

Change

Previous filing in this sequence was filed on 04 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001575202 Primary reporting owner

GUJRATHI SHEILA

Relationship: Director
Address: 601 21ST STREET, SUITE 300, VERO BEACH
Signature: /s/ Sheila Gujrathi
Signature date: 30 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Series A Preferred Stock

Award

Transaction value
Shares: +70,812
Change %
Price
Shares after: 70,812
Date: 28 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,812
Exercise price
Footnotes: F1, F2, F3

PCSA transaction Derivative

Series A Preferred Stock

Award

Transaction value
Shares: +12,311
Change %
Price
Shares after: 12,311
Date: 28 Jul 2026
Ownership: By SilverArc Private Fund I, L.P.
Underlying class: Common Stock
Underlying amount: 12,311
Exercise price
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each share of Series A Non-Voting Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into 1,000 shares of common stock of Processa Pharmaceuticals, Inc. (the "Company"). The Preferred Stock has no expiration date.

Footnote F2

Received in exchange for shares of common stock of Vidya Therapeutics, Inc. ("Vidya") pursuant to an Agreement and Plan of Merger, dated July 28, 2026 (the "Merger Agreement"), by and among the Company, Vidya, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub I"), Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Merger Sub II"), at an exchange ratio of 162.811 shares of Vidya common stock for each share of Company common stock.

Footnote F3

Under the terms of the Merger Agreement, on July 28, 2026, Merger Sub I merged with and into Vidya, with Vidya surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, Vidya merged with and into Merger Sub II, with Merger Sub II surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of Vidya converted into the right to receive shares of the Company's Series A Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock, each share of Series A Preferred Stock is convertible into 1,000 shares of the Company's common stock.

Footnote F4

The Reporting Person is Co-Portfolio Manager and has membership interest in SilverArc Private Capital I, LLC (Ultimate General Partner), SilverArc Private Capital I, LP (General Partner), and SilverArc Private Capital Management I, LP (Management Company) for SilverArc Private Fund I, L.P. The Reporting Person may not be deemed to have voting or investment power over the shares held of record by SilverArc Private Fund I, LP. The Reporting Person disclaims beneficial ownership of such securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein.